ArticleFrontiers in nutrition2026
Alginate oligosaccharides attenuate obesity-associated kidney injury through modulation of the intestinal environment with renoprotection transferable by small intestinal contents.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High-fat diet (HFD)-induced obesity is closely associated with metabolic imbalance and kidney injury. Alginate oligosaccharides (AOS) are considered promising dietary bioactive compounds; however, whether they protect against obesity-associated renal damage has not been fully clarified. In this study, we investigated whether AOS ameliorates renal injury in HFD-fed mice and further used transplantation of small intestinal contents to explore the possible involvement of gut-derived factors. Methods: After AOS treatment, metabolic parameters, renal function, kidney histopathology, and related pathological alterations were evaluated. For the transplantation experiment, small intestinal contents collected from control or AOS-treated donor mice were administered to HFD-fed recipient mice, after which renal and metabolic phenotypes were assessed. Results: AOS improved HFD-induced metabolic disorders and alleviated renal injury. Mice treated with AOS showed lower serum blood urea nitrogen and creatinine levels, reduced renal lipid accumulation, and attenuated inflammatory and oxidative stress-related changes. Notably, recipient mice receiving small intestinal contents from AOS-treated donors also exhibited partial improvement in these abnormalities, whereas contents from control donors showed weaker or less consistent effects. These findings suggest that AOS-associated alterations in small intestinal contents may contribute to the observed renoprotective effects. Conclusion: AOS attenuated obesity-associated renal injury in HFD-fed mice, and this effect was at least partially transferable through transplantation of small intestinal contents. This study provides supportive evidence that gut-derived factors are involved, at least in part, in the renoprotective effects associated with AOS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.